USFDA nod to Alembic Pharma stroke and blood clots drug Dabigatran Etexilate

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 75 mg, 110 mg, and 150 mg of Boehringer Ingelheim Pharmaceuticals, Inc..

Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients; treatment and reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients.

 Atrial fibrillation (AFib) is a type of irregular heartbeat that can lead to blood clots forming in the heart. These clots can travel to the brain and cause a stroke. DVT occurs when blood clots form in the deep veins of the legs or other parts of the body. These clots can break loose and travel to the lungs, causing a potentially life-threatening condition known as pulmonary embolism. 

Dabigatran Etexilate Capsules 75 mg and 150 mg have an estimated market size of US$ 179 million for twelve months ending Mar 2024 according to IQVIA. Dabigatran Etexilate Capsules 110 mg have an estimated market size of US$ 5 million for twelve months ending Mar 2024 according to IQVIA.

Read also: Alembic Pharma gets USFDA nod for Sacubitril and Valsartan Tablets for heart failure

Alembic has a cumulative total of 205 ANDA approvals (178 final approvals and 27 tentative approvals) from USFDA.

Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. 

Read also: USFDA approves Alembic Pharma Icatibant Injection for acute attacks of hereditary angioedema